Objectives: To investigate racial/ethnic differences in acute asthma among adults presenting to the emergency department (ED), and to determine whether observed differences are attributable to socioeconomic status (SES). Design: Prospective cohort studies performed during 1996 to 1998 by the Multicenter Airway Research Collaboration. Using a standardized protocol, researchers provided 24-h coverage for a median duration of 2 weeks per year. Adults with acute asthma were interviewed in the ED and by telephone 2 weeks after hospital discharge. Participants: Sixty-four North American EDs. Results: A total of 1,847 patients were enrolled into the study. Black and Hispanic asthma patients had a history of more hospitalizations than did whites (ever-hospitalized patients: black, 66%; Hispanic, 63%; white, 54%; p < 0.001; patients hospitalized in the past year: black, 31%; Hispanic, 33%; white, 25%; p < 0.05) and more frequent ED use (median use in past year: black, three visits; Hispanic, three visits; white, one visit; p < 0.001). The mean initial peak expiratory flow rate (PEFR) was lower in blacks and Hispanics (black, 47%; Hispanic, 47%; white, 52%; p < 0.001). For most factors, ED management did not differ based on race/ethnicity. After accounting for several confounding variables, blacks and Hispanics were twice as likely to be admitted to the hospital. Blacks and Hispanics also were more likely to report continued severe symptoms 2 weeks after hospital discharge (blacks, 24%; Hispanic, 31%; white, 19%; p < 0.01). After adjusting for sociodemographic factors, the race/ethnicity differences in initial PEFR and posthospital discharge symptoms were markedly reduced. Conclusion: Despite significant racial/ethnic differences in chronic asthma severity, initial PEFR at ED presentation, and posthospital discharge outcome, ED management during the index visit was fairly similar for all racial groups. SES appears to account for most of the observed acute asthma differences, although hospital admission rates were higher among black and Hispanic patients after adjustment for confounding factors. Despite asthma treatment advances, race/ethnicity-based deficiencies persist. Health-care providers and policymakers might specifically target the ED as a place to initiate interventions designed to reduce race-based disparities in health.
(ED) utilization by asthmatic adults of different racial/ethnic backgrounds have used retrospective reviews of archived or billing data. 18, 33 This restricts the range of variables that can be examined and leads to an incomplete picture of what actually happens to patients while they are in the ED. To further examine the role of race/ethnicity in asthma among adults presenting to the ED, we examined prospective data from the Multicenter Airway Research Collaboration (MARC). Based on previous research, we hypothesized that black and Hispanic asthma patients would be (1) in more severe respiratory distress on arrival to the ED, (2) more likely to receive substandard care while in the ED, (3) hospitalized more often during their index ED visit, and (4) more likely to relapse or have continued symptoms during the 2 weeks after hospital discharge. We further hypothesized that, after statistically controlling for factors thought to be confounders of the relation between race/ethnicity and illness severity (ie, education level, income, insurance status, and access to a primary care provider [PCP] ), the observed racial/ethnic differences either would disappear or be dramatically reduced.
Materials and Methods
We analyzed data from three prospective cohort studies performed from 1996 to 1998 as part of the MARC (http:// healthcare.partners.org/marc). The purpose of the MARC was to try to define the characteristics of patients presenting to the ED for acute asthma, to describe their management and outcome, and to follow their course after hospital discharge. Using a standardized protocol, researchers at 64 EDs in 21 US states and 4 Canadian provinces provided 24-h coverage for a median duration of 2 weeks and consecutively enrolled adult patients. The following criteria were used to determine eligibility: (1) physician-diagnosed asthma (including new diagnoses by the ED physician or patient reported history); (2) current ED visit was due to an exacerbation; (3) age 18 to 54 years (truncated at 54 in order to help rule out COPD); and (4) the ability to give informed consent. Repeat visits by individual patients were excluded. All patients were managed at the discretion of the treating physician. The site investigators were not informed that we intended to compare presentation/management/outcome by race/ethnicity. Therefore, they were blinded to the specific hypotheses studied in this investigation. The institutional review board at each hospital approved the study.
Public hospitals constituted 36% of sites. The remainder of the sites were private or not-for-profit hospitals. The median number of annual hospital admissions was 23, 427 , the median number of annual ED visits was 54,000, and the median number of annual visits for asthma was 1,500.
Data Collection
The ED interview assessed patients' sociodemographic characteristics, asthma history, and details of their current asthma exacerbation. Data on ED management, disposition, and hospital discharge medications were obtained by chart review. Follow-up data were collected by telephone interview 2 weeks later. Research personnel used "best numbers" and "best times" solicited during the ED interview to guide their calls. A minimum of five attempts to reach the patient were made, spaced across at least 3 days. All forms were reviewed for accuracy, completeness, and legibility by site investigators before submission to the MARC Coordinating Center in Boston, MA, where they underwent further review by trained personnel. Incomplete, contradictory, or illegible data were returned to the site investigator for reconciliation. The data were double-entered.
Sociodemographic Factors: Age, sex, level of education, and insurance status were recorded. Consistent with other literature in this area, 10, 11, 13, 17, 18, 33, 38 the median family income was estimated using patients' home ZIP codes. 42 Race/ethnicity was assigned by self-report to standard US Census categories. For the purpose of this analysis, mutually exclusive categories were determined as follows: black (ie, African American or nonHispanic); Hispanic; or white (ie, non-Hispanic). Patients designated as Asian or "other" ethnicity were excluded due to small numbers. While the limitations of self-report have been discussed in the literature, [43] [44] [45] [46] it remains the most common and efficient manner by which to classify patients' race/ethnicity. Patients were asked whether they had a PCP.
Chronic Asthma History: We also assessed patients' asthma medication use, including oral corticosteroids, rescue inhalers, and inhaled corticosteroids. We measured health-care utilization via hospitalization history (ever hospitalized and hospitalized in the past year), the number of ED visits made in the past year, and the source of their primary asthma care and prescriptions. Smoking status also was assessed. To examine further disease self-management, we assessed whether the patient owned a spacer device, peak flowmeter, and a written action plan. Finally, we recorded whether a comorbid medical condition was present (eg, congestive heart failure or COPD).
ED Course: We collected both subjective and objective measures of acute asthma severity. Severe symptoms was assigned to patients who reported asthma symptoms "most of the time" or had experienced "severe" discomfort and distress due to their asthma during the past 24 h. Peak expiratory flow rate (PEFR) was expressed as the percentage of the patient's predicted value, based on race, age, sex, and height. 47 Initial measurement and change in PEFR were recorded. The number of inhaled ␤-agonist treatments received prior to arrival in the ED, the number of treatments received during the ED visit (ie, within the Boudreaux, PhD, Emergency Medicine Residency Program, Cooper Hospital, One Cooper Plaza, Camden, NJ 08103-1489; e-mail: boudreaux-edwin@ cooperhealth.edu first hour and the total number), and whether the patient received oral corticosteroids were abstracted from the chart. We calculated ED length of stay and recorded ED disposition. Hospital discharge medications were recorded, including systemic and inhaled corticosteroids. However, prescription for inhaled corticosteroids at hospital discharge was systematically collected for only two of the three cohorts (566 patients). Two-Week Follow-up: All patients were called 2 weeks after their discharge from the ED. Relapse was defined as any urgent visit to an ED or clinic for worsening of asthma during the 2-week follow-up period. The number of days between discharge from the ED and the date of relapse was recorded. An ongoing exacerbation classification was assigned to patients who reported "severe symptoms" during the 24-h period preceding the phone call on any one of two questions (ie, asthma symptoms "most of the time" or "severe" discomfort and distress due to their asthma) or to those who stated that their asthma was "about the same" or "worse" than at the time of their ED presentation.
Statistical Analysis
All statistical analyses were performed using a statistical software package (STATA, version 7.0; StataCorp; College Station, TX) . The data are presented as proportions, means (with SD), or medians (with interquartile range [IQR] ). The association between race/ethnicity and other factors was examined using 2 test, analysis of variance, and Kruskal-Wallis test, as appropriate. Three multivariate models were derived to predict the initial PEFR, hospitalization, and posthospital discharge outcome. Each of these final models included the following variables: age; sex; education; median household income; insurance status; PCP status; and recent inhaled corticosteroid use. Other salient variables then were added based on the particular dependent variable (eg, initial PEFR and change in PEFR were used to predict hospitalization). The race/ethnicity variable was added to the three models as one variable. All interpretations of the odds ratios (ORs) for blacks and Hispanics were based on the reference group (whites). The possibility of a period effect was examined by adjusting for the period of enrollment, but this did not materially affect any of the results that follow (data not shown). All ORs are presented with 95% confidence intervals (CIs). All p values are two-sided. Considering the large sample size and the risk of multiple testing error, p Ͻ 0.01 was considered to be statistically significant.
Results
Among the eligible patients, 588 refused study entry, were missed, or were not enrolled for another reason, and 1,847 were enrolled into the study. Three patients were excluded because race/ethnicity data were missing. Patients identified as Asian or "other" race/ethnicity (44 patients) were excluded, since the purpose of the study was to investigate blacks and Hispanics. Patients who were enrolled did not differ from those who were not enrolled according to demographic factors, available chronic asthma factors, ED course (except for the administration of steroids in the ED, which was more likely among those who were enrolled in the study [68% vs 62%, respectively; p ϭ 0.01]), or disposition.
Among the 1,800 patients used in these analyses, 935 (52%) were black, 411 (23%) were Hispanic, and 454 (25%) were white. Since the US sites had a high proportion of black and Hispanic patients and the Canadian sites had a high proportion of white patients, we re-ran all the analyses excluding the Canadian sites. We found no significant differences in the results.
Sociodemographics
Sociodemographic characteristics by race/ethnicity are presented in Table 1 . Trends show that black and Hispanic asthma patients were from lower SES households and were less likely to have a PCP.
Chronic Asthma History
Chronic asthma history by race/ethnicity also is presented in Table 2 . Black and Hispanic patients were more likely to have a history of hospitalization and reported a greater number of ED visits. They were more likely to state that they used the ED as their primary source of asthma care and prescriptions. The three groups were equally likely to have recently used systemic corticosteroids and inhaled bronchodilators, but black and Hispanic patients were less likely to have used inhaled corticosteroids. Black patients and, especially, Hispanic patients were less likely to own a spacer and a peak flowmeter, while action plans were low across all three 26,288 (18,999-34,487) 25,185 (17,364-32,849) 35,336 (27,190-43,291 groups. Comorbid medical conditions were equally likely (blacks, 9%; Hispanics, 4%; whites, 8%; p ϭ 0.03).
Acute Presentation and ED Course
Data on acute asthma presentation and ED course are presented in Table 3 . Black and Hispanic patients exhibited more severe objective airway obstruction (based on PEFR), but blacks reported slightly less severe subjective distress. Black and Hispanic patients received more inhaled bronchodilator doses during the first hour following triage, and black patients were most likely to have received systemic corticosteroid treatment. All race/ethnicity groups were equally likely to be discharged from the ED with a prescription for inhaled corticosteroids (566 patients; black, 39%; Hispanic, 37%; white, 48%; p ϭ 0.15). When the sample was restricted to 
Two-Week Follow-up
A total of 1,308 patients (71% of total) were reached for telephone follow-up. Blacks were the least likely to be reached (likelihood: black, 66%; Hispanic, 72%; white, 80%; p Ͻ 0.001). Univariate results are presented in Table 4 . Race/ethnicity was not related to the likelihood of short-term relapse, although time to relapse among those who did relapse appeared to be longer for blacks. Blacks and, especially, Hispanics were the most likely to have ongoing symptoms at the univariate level. However, when the data were controlled for several factors (ie, age, sex, education, estimated household income, insurance status, PCP status, recent use of inhaled steroids, ED steroid treatment, and final PEFR), there was no statistically significant difference according to race/ethnicity (black vs white: OR, 1.3; 95% CI, 0.9 to 1.9; p ϭ 0.17; Hispanic vs white: OR, 0.8; 95% CI, 0.5 to 1.2; p ϭ 0.24). Approximately 33% of adults reported a relapse event or an ongoing exacerbation.
Discussion
It is widely recognized that black and Hispanic asthma patients receive substandard outpatient care, visit the ED more frequently, and are hospitalized at greater rates than are whites. 8 -18,48 However, little is known about whether racial/ethnic differences exist during the course and treatment of exacerbations while in the ED or whether racial/ethnic differences exist in relapse and outcome after discharge from the ED. Because we prospectively enrolled patients during their ED visit and observed them after their ED discharge, rather than using archival or billing data, our study helps to answer these questions. 
Racial/Ethnic Differences in Asthma on Presentation to the ED
We hypothesized that black and Hispanic patients would present to the ED in more severe respiratory distress than white patients. Consistent with this hypothesis, black and Hispanic patients in our sample presented to the ED with an average PEFR of 47% of the predicted value, compared to 52% for white patients. Our analyses indicate that this difference is not likely due to chance. Moreover, if an individual improved from 47 to 52%, this would represent a Ͼ 10% change in the patient's PEFR, which generally is considered clinically significant. Arguably, using the mean PEFR may have blurred very sick and very mild cases together, potentially hiding a trend for a continued greater rate of mild cases among black and Hispanic patients. To help explore this possibility, we further subdivided the PEFR into three groups based on National Asthma Education and Prevention Program guidelines. This distribution showed that white patients, rather than black and Hispanic patients, tended to be more likely to present with mild exacerbations.
Our multivariate analyses indicated that adjusting for demographic factors and SES markedly reduced the size of the discrepancy in severity of acute asthma by race/ethnicity. The extant literature is contradictory regarding the role that SES plays in the race/ethnic disparities observed in asthma severity, morbidity, and management. Some have found 33 results similar to ours, with all or most of the race/ethnicity-based disparities being accounted for by SES. Most others have found that race/ethnicitybased differences persist even after adjusting for SES indicators, such as annual income, 11, 17, 18 urban nature of residence, 9,10 and insurance status. 18 However, to conclude that SES is not an important mediator of race/ethnicity-based asthma disparities based on these later studies alone would be to oversimplify a very complex issue. Many of these studies found that SES was substantially related to at least some of the disparities noted, and none concluded that SES was unrelated to race-based disparities or was unimportant in understanding why such disparities occur. They simply concluded that SES was not the only factor accounting for racial/ethnic disparities.
The persisting race/ethnicity differences in morbidity and mortality, even after controlling for SES, possibly can be explained by cultural differences in the tendency to use a short-term treatment approach rather than preventive treatment approaches. However, to date, convincing data for this hypothesis have not been published in the asthma literature. Furthermore, it is clear that, by focusing on only one indicator such as insurance status or annual income, many studies simply did not sufficiently account for SES, which is a multifaceted construct. Kaufman and colleagues 49 have cautioned that residual confounding can be a significant problem when studying the health correlates of SES. For example, Zoratti and colleagues 18 found that, even among members of the same managed care organization, blacks still earned less than whites. When they isolated their sample to include only those patients who had low incomes, many (but not all) of their race/ethnicity-based discrepancies in health-care utilization and prescription medication usage disappeared or were markedly attenuated.
Racial/Ethnic Differences in ED Course and Management
Many of our results on ED course and management ran counter to the trends noted in outpatient settings. Black and Hispanic patients received more doses of inhaled ␤-agonists within the first hour of presentation, and black patients were more likely to receive oral corticosteroids than were white patients. This more aggressive treatment possibly reflects an appropriate response to the aforementioned greater severity on presentation and worse chronic history of asthma among minorities. These trends, combined with the fact that the total number of inhaled ␤-agonist treatments, the final PEFR, change in PEFR, ED length of stay, and ED discharge medications did not differ among racial/ethnic groups, indicates that patients received similar care and achieved comparable resolution of symptoms while in the ED. Other studies 50, 51 have shown that the quality of ED asthma care frequently diverges from national guidelines. However, these studies did not specifically investigate whether ED care for minorities diverged to a greater degree than that of whites, making it difficult to integrate our results. Importantly, our results affirm the common perception that the ED is a "safety net" for individuals with asthma, regardless of race/ethnicity.
Racial/Ethnic Differences in Hospitalization During the Index ED Visit
Studies 9 -11,14,17,18,38 have found that hospitalization rates among minorities are three to five times that for whites during a given period. However, we could not identify any published studies that actually have investigated racial/ethnic differences in hospital admission rates during an index ED visit. We expected moderate-to-large racial/ethnic differences in hospitalization at the index visit. To the contrary, we found almost identical rates, in absolute terms, among all three groups. Approximately 20% of all blacks, Hispanics, and whites were hospitalized during their index visit.
The discrepancy between hospitalization point incidence (ie, at the index ED visit) and period incidence (ie, 1 year) is difficult to explain. It seems likely that it is due, at least in part, to a base-rate effect. Even though black and Hispanic patients have the same risk of being hospitalized during a given ED visit, they may have a markedly greater incidence of hospitalization over a given period, because they experience severe exacerbations warranting emergency care more frequently. This can be conceptualized in probabilistic terms. The chance of rolling a six on any roll of a die is identical. Nevertheless, one has a better chance of rolling at least one six during a given period of time if allowed to roll the die three times instead of only once. Even though a black patient has a similar probability of being admitted to the hospital at a given visit, if that patient presents three times over the course of a year and a white patient presents only once, the black patient will be more likely to be admitted to the hospital during that year.
Although the absolute rates of hospitalization were roughly equivalent, our multivariate analyses revealed an interesting trend. Once all sociodemographic factors, initial PEFR, and change in PEFR were controlled for, black and Hispanic patients were more than twice as likely to have been admitted to the hospital. The inclusion of PEFR indexes in the last step of the model appeared to have the largest impact on the race/ethnicity-hospitalization relationship. This finding seems to suggest that, at equivalent levels of symptom resolution, black and Hispanic patients are more likely to be admitted to the hospital than whites. The reasons for this association are difficult to determine and await further empirical validation.
The Role of Race/Ethnicity and Posthospital Discharge Outcome
The posthospital discharge outcomes present a mixed picture. Blacks and Hispanics sought urgent medical care within the 2 weeks after hospital discharge at approximately the same rate as whites (approximately 15%), although blacks appeared to have a longer delay before seeking such care. Whether this is due to a delay in seeking treatment or a delay in experiencing an exacerbation severe enough to warrant treatment is not clear. Our relapse rates were comparable to those reported by other single-center studies. [52] [53] [54] Treatment failure, defined by the continued self-report of severe symptoms, occurred more frequently in minorities, particularly Hispanics. As with the racial/ethnic differences noted in initial PEFR on presentation to the ED, the race-based discrepancy in treatment failure appears to be associated primarily with racial/ethnic differences in sociodemographic factors, including SES.
Potential Limitations
In evaluating our results, several potential limitations should be considered. First, we recognize that the race/ethnicity designation, though ubiquitous in epidemiologic research, may be misleading, and that standard census classification is simplistic. Nevertheless, our designations are consistent with those used in prior studies cited throughout our article. Such research remains common and is important in order to further understand and eventually to modify the reasons why such differences exist. The fact that race/ethnicity is difficult to operationalize does not mean we should not study it. Research such as ours is important in raising public awareness and may help providers to counteract any implicit racism that may be present.
Second, our sample size was large, which enabled us to detect small differences that were not necessarily clinically meaningful. We were sensitive to this fact, however, and emphasized only those trends that appeared clinically significant, noting in the text when such a problem might exist.
Third, the EDs that comprised our sample are predominantly urban, academically affiliated hospitals. This may make our results less generalizable to community hospitals without academic affiliation. Future studies need to address this issue.
Fourth, we noted a paradoxical trend in initial severity. Despite presenting with worse PEFR, black patients reported slightly less severe symptoms than whites. The reason for this is unclear. The differences were not likely due to chance, but the magnitude was small and may not be clinically meaningful. The observation awaits validation by other studies. It is a potentially important area, since blunted perception of dyspnea has been associated with the increased risk of near-fatal asthma. 55, 56 Finally, we found that hospital discharge medications did not differ based on race. However, since black and Hispanic patients had more severe chronic asthma, the fact that the ED discharge rates were equal for inhaled corticosteroids is somewhat disconcerting. Under these conditions, one would logically expect that the ED discharge rates for inhaled corticosteroids should be greater for blacks and Hispanic patients. Consequently, the equal rates of ED discharge on inhaled corticosteroids may actually be interpreted to mean that blacks and Hispanics were undertreated on ED discharge. 
Integration
The associations among race/ethnicity, SES, and various measures of asthma severity and morbidity are complex. We found marked racial/ethnic differences in chronic asthma management. Black and Hispanic asthma patients lacked PCPs more often, reported a greater likelihood of lifetime hospitalization, and reported more numerous ED visits in the past year. Importantly, they also were less likely to use inhaled corticosteroids and less frequently owned a spacer and a peak flowmeter. Not only do they present to the ED more often, but also our data show that they presented to the ED with somewhat more severe exacerbations. However, their course and treatment during the ED visit did not seem to differ dramatically, they were not hospitalized during their index ED visit at greater rates than whites (except when controlling for confounding factors), and they did not seek urgent medical care within the 2 weeks after hospital discharge more frequently than whites. As mentioned earlier, the reason that minorities exhibit such deficient chronic asthma management is probably, at least in part, due to SES and the substandard health care that accompanies lower SES. Other environmental factors associated with low SES may lead to deficient chronic disease management, such as increased risk of respiratory infections due to overcrowding, and greater exposure to allergens and irritants, 13, 35, 38, 41 but these were not assessed in our study. Although we found that most differences were attributable to differences in SES, other research 49 suggests that residual race/ethnicity differences may still be present even after adjusting for SES. This implicates other sociocultural and psychological factors. Some authors have speculated that racial/ethnic discrimination among health-care providers is a possible cause for the inequities observed in health care, 43, 57 although it is probably not conscious or deliberate. 58 Several other explanations have been mentioned in the literature but have not been researched well enough to form conclusions. At best they offer direction for future research. These include race-based differences in health beliefs and practices emphasizing rescue rather than preventive strategies, 18, 59, 60 impaired illness perception and judgment of disease severity, 13, [61] [62] [63] lower selfefficacy regarding asthma management, 64 -67 and greater comorbid psychopathology, such as depression, anxiety, and panic disorders. 64, 65 The elimination of health disparities by race/ ethnicity is an overarching goal of Healthy People 2010. Although race-based disparities are trenchant and difficult to address, they can and should be eliminated. Evidence 68 has shown that the deficient asthma care in economically disadvantaged healthcare facilities can be rectified with education and supportive programs. The necessary changes are unlikely to occur on a broad scale, however, without massive, coordinated, and sustained effort by all concerned parties, including the federal government, health-care providers and organizations, the pharmaceutical industry, community and civic associations, patient-advocacy groups, and the patients themselves.
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